The Joint's revenue for the
three
months ended in Mar. 2026 was $14.82 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $56.64 Mil.
The Joint's Revenue per Share for the
three
months ended in Mar. 2026 was $1.05.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $3.81.
Warning Sign:
The Joint Corp revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of The Joint was 9.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -18.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -7.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 11.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, The Joint's highest 3-Year average Revenue per Share Growth Rate was 65.50% per year. The lowest was -18.90% per year. And the median was 26.70% per year.
The Joint (NAS:JYNT) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
The Joint Revenue Related Terms
The Joint Revenue Historical Data
* Premium members only.
The historical data trend for The Joint's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, The Joint's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Joint Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Joint's Revenue distribution charts can be found below:
* The bar in red indicates where The Joint's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $56.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Joint (JYNT) has a Revenue of $56.64 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on The Joint and its competitors.
Is The Joint's Revenue too high?
The Joint's current Revenue is $56.64 Mil. Overall, The Joint has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Joint's Revenue compare to PARK and WW?
The Joint's Revenue of $56.64 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on The Joint and its competitors. The Joint's current Revenue is $56.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Joint stock overvalued right now?
Based on GuruFocus' analysis, The Joint (JYNT) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.14, compared to a current price of $8.97 — trading 19.5% below its estimated fair value. The current Revenue is $56.64 Mil. The Joint's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For The Joint (JYNT), the current Revenue is $56.64 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Joint (JYNT) Overvalued in 2026?
Based on GuruFocus' analysis, The Joint stock appears to be undervalued.
The current stock price of $8.97 is trading 19.5% below its estimated GF Value™ of $11.14.
GuruFocus considers The Joint to be Modestly Undervalued.
Key valuation signals for JYNT:
Revenue: $56.64 Mil
GF Value™: $11.14 vs. price of $8.97 (19.5% below fair value)
No single metric tells the full story. See the JYNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.
62GF Score
Get the complete analysis for JYNT
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JYNT has been successfully added to your 
